Psilocybin and Cocaine Addiction: Clinical Research and Policy Outlook

Psilocybin Research Expands to Stimulant Use Disorders

Psilocybin, a classic psychedelic compound found in certain mushrooms, is increasingly studied as a potential treatment for substance use disorders, including cocaine addiction. While recent headlines highlight this emerging application, as of November 2026, no phase 3 clinical trials for psilocybin in cocaine use disorder (CUD) are registered in major databases such as ClinicalTrials.gov. Most published research remains at the preclinical or early-phase human trial stage, with small sample sizes and open-label designs predominating.

Notably, a 2023 phase 2 study (NCT05032852) at the University of Alabama at Birmingham explored psilocybin-assisted psychotherapy for CUD, enrolling 40 participants. Results, presented at the American College of Neuropsychopharmacology, suggested reductions in cocaine use, but peer-reviewed publication and replication are pending. The field is thus at an inflection point, with growing scientific interest but limited definitive evidence.

Mechanisms: How Psilocybin May Affect Cocaine Addiction

Psilocybin is hypothesized to reduce cocaine craving and relapse risk through its action as a serotonin 2A receptor agonist, modulating brain circuits involved in reward, habit, and self-reflection. Early neuroimaging studies indicate that psilocybin may disrupt maladaptive patterns of connectivity in the default mode network, which are implicated in compulsive drug-seeking behaviors.

Preclinical research in rodents has shown that psilocybin can attenuate cocaine-induced behavioral sensitization and reduce self-administration. In humans, pilot data suggest that the combination of psilocybin and structured psychotherapy may enhance motivation for change and support sustained abstinence. However, these mechanisms remain theoretical pending larger, controlled studies. A critical, under-discussed challenge is the heterogeneity of cocaine addiction phenotypes, which may influence who benefits from psychedelic interventions.

Policy and Regulatory Context

Psilocybin remains a Schedule I substance under the United States Controlled Substances Act and equivalent schedules in most jurisdictions, including the United Kingdom and European Union. The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for psilocybin in major depressive disorder (MDD) and treatment-resistant depression (TRD), but not for any stimulant use disorder as of November 2026. No Investigational New Drug (IND) applications for psilocybin in CUD have advanced to pivotal trials.

Regulatory agencies require robust safety and efficacy data from randomized, double-blind, placebo-controlled trials before considering approval for new indications. The absence of such data for psilocybin in cocaine addiction means clinical use remains off-label and largely confined to research settings. Policymakers and institutional review boards (IRBs) are closely watching for adverse event profiles, especially given the high comorbidity of psychiatric conditions in CUD populations.

Risks, Unknowns, and Clinical Cautions

The safety profile of psilocybin is generally favorable in medically screened populations, but significant risks remain for individuals with a history of psychosis, bipolar disorder, or uncontrolled cardiovascular disease. In the context of CUD, additional concerns include potential drug-drug interactions, destabilization of mood, and the risk of exacerbating underlying psychiatric symptoms.

Long-term outcomes, optimal dosing protocols, and the durability of treatment effects are not yet established. Furthermore, the integration of psychedelic therapy into existing addiction treatment frameworks raises operational and ethical questions, including therapist training, patient selection, and informed consent. A notable failure mode, rarely discussed in public reporting, is the risk of "expectancy effects"—patients anticipating transformative results may experience disappointment or disengagement if benefits do not materialize, potentially undermining engagement with evidence-based care.

Outlook: Next Steps for Research and Policy

Definitive answers on psilocybin's role in treating cocaine addiction will depend on the initiation and completion of larger, well-controlled trials. Stakeholders should monitor for updates to trial registries, FDA guidance, and peer-reviewed publications. Cross-disciplinary collaboration between neuroscientists, addiction specialists, and regulatory experts will be essential to address the unique challenges posed by stimulant use disorders.

For now, psilocybin for cocaine addiction remains a promising but unproven approach. The coming years will clarify whether this psychedelic can meaningfully expand the toolkit for treating one of the most persistent and difficult substance use disorders.

By Dr. Jamie Lin, PhD (Neuroscience, Policy Editor). Reviewed by Dr. Marcus Patel, MD, on 2026-11-07. Research based on primary trial registry data, FDA statements, and peer-reviewed literature as of November 2026.